OncoZenge

The MASCC annual meeting is a premier gathering of healthcare professionals dedicated to improving the quality of life for cancer patients. The conference focuses on the latest advancements and best practices in cancer supportive care.

OncoZenge will be represented by Board member Christoph Nowak, MD, PhD, who will present an abstract at the conference on the planned European Phase 3 study for BupiZenge™ targeting oral mucositis pain in cancer patients. The conference provides a unique opportunity for OncoZenge to engage with Key Opinion Leaders.

“We are excited to participate at MASCC 2025,” said Dr. Nowak. “This is a great opportunity to present our registrational study plans and engage with experts, patient advocates and clinicians in the field”.

The overall theme of MASCC 2025 is ‘Informed Decisions in Supportive Cancer Care’. The Chair of the Mucositis Study Group at MASCC, Dr. Paolo Bossi, a Medical Oncologist and Associate Professor at the Humanitas Cancer Center in Milan, Italy, also serves as a member of the OncoZenge Advisory Board.

BupiZenge™ – Potential to be the leading treatment for oral pain.

 
For additional information, please contact:
Christoph Nowak, e-mail: christoph.nowak@oncozenge.se
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se

Certified Adviser
OncoZenge’s Certified Adviser is Redeye AB.

OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden

About this release
The information in this release was submitted for publication, through the agency of the contact persons set out above, at 16:40 CEST on April 2 2025.

About OncoZenge
OncoZenge is dedicated to developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options fall short, often due to insufficient pain relief or significant side effects. BupiZenge™ is a novel oral lozenge formulation of bupivacaine, a local anesthetic with decades of clinical experience. The lead indication for BupiZenge™ is oral pain caused by oral mucositis, an inflammatory condition affecting millions of cancer patients. Oral mucositis leads to severe physical and psychological distress, representing a significant unmet medical need for an effective, opioid-sparing treatment. In Phase 2 trials, BupiZenge™ demonstrated substantially better pain relief compared to the standard of care.

OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.